Shield Therapeutics reports 56% revenue growth and positive cash flow in 2025

ru.investing.com (Russian)

Shield Therapeutics reported a 56% revenue increase to $49.7 million for 2025, driven by strong US sales of ACCRUFeR. The company achieved positive operating cash flow in Q4 2025 and reduced its annual loss. ACCRUFeR saw a 21% rise in net selling price and expanded its approved indications. Shield Therapeutics also expanded its debt facility and saw international progress, with regulatory submissions and partnerships in Europe, Canada, South Korea, and Japan.


With a significance score of 1.4, this news ranks in the top 38% of today's 30408 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Shield Therapeutics reports 56% revenue growth and positive cash flow in 2025 | News Minimalist